Baxalta Us Inc. Sustainability Profile
Baxalta US Inc., a prominent biopharmaceutical company, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its expertise in haematology, immunology, and oncology, offering a range of unique products that address unmet medical needs. Baxalta's core offerings include advanced biologics and specialty pharmaceuticals, distinguished by their commitment to patient-centric solutions and cutting-edge research. With a strong market position, Baxalta has achieved notable milestones, including significant advancements in treatment options for bleeding disorders. The company continues to be a leader in the biopharmaceutical industry, dedicated to improving patient outcomes through innovation and excellence.
DitchCarbon Score
How does Baxalta Us Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Baxalta Us Inc.'s score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Baxalta US Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of available figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Baxalta's climate strategy is aligned with the broader goals set by its parent company, Takeda. While no specific reduction targets or achievements are listed for Baxalta, it is important to note that emissions data and climate initiatives may be cascaded from Takeda, which operates under established frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As a subsidiary, Baxalta's climate commitments are likely informed by Takeda's overarching sustainability goals, which include significant efforts to reduce carbon emissions across all scopes. However, without specific data or targets from Baxalta itself, the details of its individual climate commitments remain unclear. In summary, while Baxalta US Inc. does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate action through its parent company, Takeda Pharmaceutical Company Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Baxalta Us Inc.'s Industry?
How Carbon Intensive is Baxalta Us Inc.'s Location?
Baxalta Us Inc.'s Scope 3 Categories Breakdown
Baxalta Us Inc.'s Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.
Top Scope 3 Categories
Baxalta Us Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Baxalta Us Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
